Zogenix Inc (ZGNX.OQ)
15 Dec 2017
Mon, Dec 4 2017
* ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME
* Zogenix provides corporate update and reports third quarter 2017 financial results
* Zogenix announces closing of public offering of common stock, including full exercise of underwriters’ option to purchase additional shares Source text for Eikon: Further company coverage:
* Files for potential mixed shelf filing; size not disclosed - SEC filing Source text : (http://bit.ly/2xOgvG9) Further company coverage:
Zogenix Inc's experimental treatment for a rare form of epilepsy met the main goal in a late-stage study, the company said on Friday, more than doubling the value of its shares and hurting those of peer GW Pharmaceuticals .
* Analyst expects drug to become standard in Dravet treatment
* Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome
Sept 29 Zogenix Inc said on Friday its experimental treatment for a rare form of epilepsy met the main goal in a late-stage study.
* Zogenix provides corporate update and reports second quarter 2017 financial results
* Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing